TrialBritish journal of cancer2019

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.

Chris Twelves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.